Skip to main content

Mission and Goals

Our Mission

The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium will enroll patients with sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The goals of the CReATe consortium are to advance therapeutic development for this group of neurodegenerative disorders through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers.


  1. Team Science: Promote and facilitate collaborative research in the field of ALS and related disorders
  2. Trials Preparation: Establish a firm foundation for future clinical trials in homogeneous patient populations by defining phenotype-genotype relationships in ALS and related disorders
  3. Biomarkers: Identify and develop biomarkers (both wet and dry) of disease progression that may enhance therapeutic development efforts
  4. Education: Train clinician-scientists focused on therapy development for patients with ALS and related disorders
  5. Relevance to Other Rare Diseases: Pioneer an innovative approach to the study of phenotype-genotype relationships that is relevant and applicable to other rare diseases
  6. Outreach/Advocacy: Engage both the lay- and scientific-community stakeholders in a partnership that will enhance scientific research and therapeutic development for patients with ALS and related disorders
  7. Biorepository: Develop and maintain a repository of biological samples from phenotypically well-characterized individuals, for use by Consortium members and the broader scientific community, for future biomarker development